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Abstract: Cytomegalovirus (CMV) is the most common intraocular opportunistic infection 
in profoundly immunocompromised patients with AIDS. It is characterized by an acute, 
progressive, necrotizing retinitis in patients with a CD4 count of ,50 cells/µL. Although the 
incidence of CMV retinitis has declined because of the introduction of antiretroviral therapy 
(ART), a new syndrome of intraocular inflammation has emerged in patients with rising CD4 
lymphocyte counts following ART. This is called immune recovery uveitis (IRU). It is thought 
to occur as a result of restored immunity to various infectious agents, commonly mycobacterial, 
Cryptococcus, and herpes virus infections. We report a man who was treated for CMV retinitis 
and later developed IRU in the form of cystoid macular edema (CMO) even though his CMV 
retinitis remained inactive. His CMO resolved and visual acuity improved 2 years after the onset 
of CMO without any treatment interventions.
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Summary
Cytomegalovirus (CMV) is the most common intraocular opportunistic infection in 
profoundly immunocompromised patients with AIDS. It is characterized by an acute 
progressive necrotizing retinitis in patients with a CD4 count of ,50 cells/µL.1 Although 
the incidence of CMV retinitis has declined because of the introduction of antiretroviral 
therapy (ART), a new syndrome of intraocular inflammation has emerged in patients 
with rising CD4 lymphocyte counts. This is called immune recovery uveitis (IRU).2,3 
It is thought to occur as a result of restored immunity to various infectious agents, com-
monly mycobacterial, Cryptococcus, and herpes virus infections.4 We report a man who 
was treated for CMV retinitis and later developed IRU in the form of cystoid macular 
edema (CMO) even though his CMV retinitis remained inactive.
Case report
In April 2008, a 45-year-old man presented with floaters and blurring of vision of his 
right eye for 6 days. Examination of the fundus revealed a nasal area of pallor extending 
from the periphery towards the centre. The visual acuity was 6/24. There was a moderate 
vitritis but no evidence of retinal hemorrhages (Figure 1). Examination result of left eye 
was normal. A diagnosis of acute retinal necrosis was made. Total blood count revealed 
lymphocytes of 0.5 × 109/L and platelets of 107 × 109/L. Total plasma protein was 
92 g/L. The human immunodeficiency virus (HIV) test was requested and was found 
positive. The CD4 count was 42 cells/mm3 (9%), and HIV RNA (viral load [VL]) level 
was 1.4 million copies/mL. Polymerase chain reaction (PCR) of the aqueous humor Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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was positive for CMV but negative for herpes simplex and 
varicella-zoster virus. The CMV PCR in blood was 2.5 × 105 
copies/mL. He was treated with five courses of intravenous 
cidofovir. His CMV PCR in the blood became undetectable. 
ART was commenced in June 2008. After 4 weeks of ART, 
the CD4 count had risen to 200 cells/mm3 (18%), and VL 
dropped to 6,602. Visual symptoms improved. In October 
2008, he noticed blurring of vision in the right eye with a 
visual acuity of 6/24. His optical coherence tomography 
(OCT) scan showed CMO (Figure 2). Fundoscopy did not 
show any evidence of active CMV retinitis. The patient 
declined intravitreal triamcinolone. In April 2010, his visual 
acuity improved to a level of 6/12. The OCT of the right 
fundus showed a normal foveal dip.
Discussion
In a study by Karavellas et al,5 the prevalence of IRU varied 
from 38% to 63% in patients with CMV retinitis. The median 
time to develop IRU was 45 weeks. Our patient developed 
IRU 8 weeks after ART. IRU is associated with CMV retini-
tis and rapid increases in CD4 counts following ART. Our 
patient developed CMV retinitis and responded well to ART 
by showing a rise in CD4 counts and a dramatic drop in VL. 
As in our patient, in a study by Karevellas et al6 all patients 
with IRU had inactive CMV retinitis at their presentation. 
CMV-related vitritis has been reported before the introduc-
tion of ART but was associated with active CMV retinitis.
The clinical spectrum of IRU includes vitritis, CMO, 
epiretinal membranes, and papillitis.6 Our patient devel-
oped CMO. Another risk factor for IRU includes surface 
area of retinal involvement due to CMV retinitis. Patients 
with .30% of retinal area affected had 4.5-fold higher 
risk of developing IRU when compared with eyes with a 
retinal CMV area of ,18%.7
Immunohistological examination of epiretinal membrane 
associated with IRU showed evidence of chronic inflammation 
with predominant T-lymphocytes. This data, in conjunction 
with the finding of a positive correlation between IRU and 
surface area of inactive CMV retinitis, would suggest that 
IRU may be due to T-cell mediated reaction to CMV antigen 
present in inactive CMV retinitis.8 The question is whether 
anti-CMV therapy may provide effective treatment for IRU. 
Although a study showed a beneficial effect of valganciclovir, 
other studies failed to prove any beneficial effects.8,9
Four cases with CMO were treated with various treat-
ments: one with a systemic prednisolone, two with injections 
of triamcinolone,10,11 and one with oral acetazolamide and 
local ketorolac trimethamine. Visual acuity improved by one 
line in all patients. In another study, corticosteroid treatment 
for five severe cases of IRU resulted in improvement in visual 
acuity without any reactivation of CMV retinitis. However, 
the use of steroid did not influence the outcome of patients 
whether they were treated early or those who were treated 
later. His CMO resolved 2 years following the onset without 
any steroid or anti-CMV treatment.
In conclusion, ophthalmologists who have a patient 
with acute retinal necrosis should be alert to the possibility 
of underlying HIV infection and CMV retinitis. This is 
particularly important in patients with lymphopenia, throm-
bocytopenia, and high globulin as in our case. In addition, 
a deterioration of visual acuity in patients who have been 
treated for CMV retinitis does not necessarily indicate a 
relapse. Clinicians should be aware of IRU in patients who 
respond to ART and consider clinical observation with mas-
terly inactivity because in some patients the condition is mild 
Figure 1 Nasal pallor extending from periphery towards the center without any 
evidence of hemorrhages.
Figure 2 Optical coherence tomography showing cystoid macular edema.Clinical Ophthalmology
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and transient, as in our case. Local steroid injection may be 
indicated in severe cases of macular edema.
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